Evogene Ltd. (NASDAQ:EVGN) is expected to report third quarter earnings results, before market open, on Wednesday 18th November 2020.
Previous Quarter Performance
Evogene Ltd. unfold loss for the second quarter of $ 0.16 per share, from the revenue of $ 0.30 million. The consensus estimates are $ 1.90 million in revenue The top line results fell short of analysts by $ 1.6 million or 84.21 percent.
Stock Performance
Shares of Evogene Ltd. traded up $ 0.59 or 24.48 percent on Tuesday, reaching $ 3.00 with volume of 2.02 million shares. Evogene Ltd. has traded high as $ 3.10 and has cracked $ 2.45 on the downward trend
According to the previous trading day, closing price of $ 3.00, representing a 221.33 % increase from the 52 week low of $ 0.75 and a 54.53 % decrease over the 52 week high of $ 5.30.
The company has a market capital of $ 109.65 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Evogene Ltd. will be hosting a conference call at 9:00 AM eastern time on 18th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 1-888-281-1167 U.S. or +972-3-918-0609 Outside U.S. in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.evogene.com
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica.
